Enliven Therapeutics, Inc. ELVN
Enliven Therapeutics, Inc. (Nasdaq: ELVN) is an oncology drug developer. Its lead program, ELVN-001, is in Phase 1 for chronic myeloid leukemia (CML), heavily pretreated and 2L+.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ELVN-001 | CML (Phase 1 ENABLE; Phase 3 ENABLE-2 planned) | small molecule | Phase 1 |
Recent results and decisions
- Jun 11, 2026positive Updated Phase 1b: 61% overall MMR (48% achieved MMR by 24 weeks) in 80 mg QD cohort; 54% overall MMR in all Phase 1b (n=69); Grade>=3 TEAEs 34% overall, 6% discontinued for AEs.
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.